Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

RegeneRx advancing pipeline candidates [Seeking Alpha]

REGENERX BIOPHARMS INC (RGRX) 
NASDAQ:AMEX Investor Relations: regenerx.com/investors
Company Research Source: Seeking Alpha
In an update for investors, RegeneRx Biopharmaceuticals ( OTCQB:RGRX ) announces its progress on two pipeline candidates. RGN-259: A Phase 3 clinical trial, ARISE-3, evaluating the preservative-free eye drop in dry eye syndrome should launch soon. The protocol has been finalized, product manufacturing completed and funding is moving forward. Talks with potential development partners are ongoing. RGN-137: Design for a Phase 3 study evaluating the dermal gel for wound healing in patients with epidermolysis bullosa is being revised per FDA guidelines. The study should launch in 2019. Production for an Open Study has been completed. Click to subscribe to real-time analytics on RGRX Now read: Vertex: Great Company But Too Pricey » Subscribe for full text news in your inbox Show less Read more
Impact Snapshot
Event Time:
RGRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for RGRX alerts
Opt-in for
RGRX alerts

from News Quantified
Opt-in for
RGRX alerts

from News Quantified